Cargando…
Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality
Aberrant activation of several signaling pathways has been implicated in prostate cancer (PCa) progression to castrate-resistant prostate cancer (CRPC). Phosphoinositide-3-kinase/Protein Kinase B/mechanistic Target of Rapamycin (PI3K/AKT/mTOR) and Hedgehog/GLI (Hh/GLI) pathways are major participant...
Autores principales: | Youssef, Mohamed, Moussa, Nermine, W. Helmy, Maged, Haroun, Medhat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283339/ https://www.ncbi.nlm.nih.gov/pubmed/35834137 http://dx.doi.org/10.1007/s12032-022-01718-8 |
Ejemplares similares
-
GANT61/BI-847325 combination: a new hope in lung cancer treatment
por: El-Kishky, Abdel Halim M., et al.
Publicado: (2022) -
The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells
por: Gonnissen, Annelies, et al.
Publicado: (2017) -
The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo
por: Gonnissen, Annelies, et al.
Publicado: (2016) -
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
por: Li, Jianlong, et al.
Publicado: (2016) -
Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib
por: Liu, Guoqiang, et al.
Publicado: (2020)